Core Viewpoint - The transformation of Northeast Pharmaceutical over the past seven years highlights its shift from traditional manufacturing to a focus on biopharmaceutical innovation, driven by mixed-ownership reform and a commitment to social responsibility [1][5]. Group 1: Company Transformation - Since joining the Liaoning Fangda Group in 2018, Northeast Pharmaceutical has broken free from institutional constraints and embraced innovation, leading to high-quality development [1]. - The company has successfully transitioned from a rigid structure to a vibrant, market-responsive organization, emphasizing biopharmaceutical advancements [1][5]. Group 2: Commitment to Public Welfare - Northeast Pharmaceutical offers affordable medications, such as acetaminophen tablets priced at 2.00 yuan per pack, reflecting its dedication to public health and accessibility [2]. - The company has invested nearly 300 million yuan in social welfare initiatives over the past seven years, demonstrating its commitment to corporate social responsibility [2]. Group 3: Employee Engagement and Innovation - The company has established effective channels for employee suggestions, resulting in the acceptance of over 900 out of 1,345 proposals in the past year, fostering a culture of innovation [4]. - A reward mechanism has been implemented, with over 27 million yuan allocated for innovation incentives in the last three years, enhancing employee motivation and creativity [4]. Group 4: Focus on Biopharmaceutical Innovation - Northeast Pharmaceutical has increased its R&D investment and adopted a three-pronged approach of independent research, joint development, and project acquisition to establish a foothold in the biopharmaceutical sector [5]. - The establishment of a biological research base in Shanghai and the acquisition of Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. have positioned the company in the cell therapy market, developing over ten targeted cell therapy products for various cancers [5]. - The company is actively recruiting PhD and master's level talent to strengthen its research capabilities, aiming to become a leader in the biopharmaceutical field [5].